114
Participants
Start Date
April 30, 2013
Primary Completion Date
August 31, 2016
Study Completion Date
August 31, 2016
LDE225
LDE225 800 mg once daily dosing will begin on Cycle 1 Day 1 of a 28-day cycle.Treatment with LDE225 for both groups will continue until the patient experiences unacceptable toxicity that precludes further treatment, disease progression, withdrawal of consent and/or at the discretion of the investigator.
Wafarin
15 mg single dose of warfarin (oral tablet) will be given to patients.
Bupropion
75 mg single dose of bupropion(oral tablet, from an immediate release formulation) will be given to patients
University of Pittsburgh Cancer Institute UPMC Cancer Pavilion, Pittsburgh
University of Pennsylvania--Abramson Cancer Center Abramson Cancer Center, Philadelphia
Medical University of South Carolina Dept.of Neurosciences/MS Ctr., Charleston
Cancer Centers of the Carolinas SC, Greenville
Karmanos Cancer Institute, Detroit
University of Kansas Medical Center CBYM338B2203, Kansas City
Utah Health Science Center at San Antonio, San Antonio
University of Utah / Huntsman Cancer Institute, Salt Lake City
City of Hope National Medical Center Oncology, Duarte
Massachusetts General Hospital Dana-Farber Cancer Institute, Boston
Dartmouth Hitchcock Medical Center Dartmouth-Hitchcock Med Ctr, Lebanon
Hackensack University Medical Center Dept.of HackensackUniv.MedCtr., Hackensack
Fox Chase Cancer Center, Philadelphia
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY